Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology

Cancer Chemotherapy and Pharmacology(1994)10.1007/bf00686108Source: DataRank Database

Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology is a research paper published in Cancer Chemotherapy and Pharmacology (1994). On theSindex it has a DataRank of 0.533. It has been cited 34 times.

N/A

0.533DataRank · unranked

Scored on demand from live citation data

34 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 2.64)OA: closedTopics (31)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.533

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (4)

L. E. Robertson,M. J. Keating,W. Plunkett,V. Gandhi

Live enrichment

PubMed:8174200 OpenAlex:https://openalex.org/W2042010784

NCI NIH HHS

Grant: CA32839

NCI NIH HHS

Grant: CA57629

FWCI

2.64

Citation Percentile

0.9%

Citation Trend

2012

2013

2017

closedLicense: http://www.springer.com/tdm

publisherhttp://link.springer.com/content/pdf/10.1007/BF00686108.pdf

publisherhttp://link.springer.com/article/10.1007/BF00686108/fulltext.html

publisherhttp://link.springer.com/content/pdf/10.1007/BF00686108

journalhttps://doi.org/10.1007/bf00686108

repositoryhttps://pubmed.ncbi.nlm.nih.gov/8174200

Fields of Study

Chronic Lymphocytic Leukemia ResearchAcute Lymphoblastic Leukemia researchAcute Myeloid Leukemia Research

MeSH Terms

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsArabinofuranosylcytosine TriphosphateArabinonucleotidesCytarabineDrug Administration ScheduleDrug SynergismFemaleHumansMaleMiddle AgedVidarabineLeukemia, Lymphocytic, Chronic, B-CellSurvival AnalysisTreatment Outcome

Keywords

FludarabineChronic lymphocytic leukemiaMedicineInternal medicineGastroenterologyChemotherapyRefractory (planetary science)Progressive diseasePharmacologyLeukemiaCyclophosphamideBiology

Sustainable Development Goals

SDG 0: Good health and well-being

Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology

FAIR Checklist

DataRank Breakdown

Authors (4)

Funding (2 grants)

Impact

Open Access

Topics